ProShare Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-35,988
| Closed | -$1.42M | – | 1899 |
|
|
2023
Q2 | $1.42M | Buy |
35,988
+10,481
| +41% | +$370K | ﹤0.01% | 684 |
|
|
2023
Q1 | $621K | Sell |
25,507
-1,792
| -7% | -$39.2K | ﹤0.01% | 840 |
|
|
2022
Q4 | $584K | Buy |
27,299
+4,301
| +19% | +$91.8K | ﹤0.01% | 887 |
|
|
2022
Q3 | $412K | Buy |
22,998
+806
| +4% | +$10.6K | ﹤0.01% | 983 |
|
|
2022
Q2 | $213K | Sell |
22,192
-11,354
| -34% | -$143K | ﹤0.01% | 1432 |
|
|
2022
Q1 | $565K | Sell |
33,546
-7,696
| -19% | -$114K | ﹤0.01% | 1206 |
|
|
2021
Q4 | $689K | Buy |
41,242
+5,644
| +16% | +$92.5K | ﹤0.01% | 1247 |
|
|
2021
Q3 | $578K | Sell |
35,598
-4,116
| -10% | -$44.8K | ﹤0.01% | 1121 |
|
|
2021
Q2 | $251K | Buy |
39,714
+5,853
| +17% | +$37.8K | ﹤0.01% | 2003 |
|
|
2021
Q1 | $209K | Buy |
33,861
+2,245
| +7% | +$13.6K | ﹤0.01% | 2015 |
|
|
2020
Q4 | $218K | Buy |
+31,616
| New | +$202K | ﹤0.01% | 1805 |
|
|
2017
Q4 | – | Sell |
-20,244
| Closed | -$57K | – | 1808 |
|
|
2017
Q3 | $57K | Buy |
20,244
+1,842
| +10% | +$4.97K | ﹤0.01% | 1341 |
|
|
2017
Q2 | $47K | Sell |
18,402
-4,220
| -19% | -$11.5K | ﹤0.01% | 1419 |
|
|
2017
Q1 | $83K | Sell |
22,622
-5,860
| -21% | -$24.8K | ﹤0.01% | 1523 |
|
|
2016
Q4 | $138K | Buy |
28,482
+2,547
| +10% | +$75.6K | ﹤0.01% | 1655 |
|
|
2016
Q3 | $1.2M | Sell |
25,935
-4,124
| -14% | -$233K | 0.02% | 635 |
|
|
2016
Q2 | $1.53M | Buy |
30,059
+1,061
| +4% | +$52.7K | 0.02% | 600 |
|
|
2016
Q1 | $1.23M | Sell |
28,998
-2,565
| -8% | -$131K | 0.02% | 630 |
|
|
2015
Q4 | $2.48M | Buy |
31,563
+2,802
| +10% | +$162K | 0.03% | 443 |
|
|
2015
Q3 | $1.17M | Sell |
28,761
-1,634
| -5% | -$86.6K | 0.02% | 625 |
|
|
2015
Q2 | $1.58M | Buy |
30,395
+603
| +2% | +$30K | 0.02% | 588 |
|
|
2015
Q1 | $1.39M | Buy |
29,792
+4,528
| +18% | +$235K | 0.02% | 686 |
|
|
2014
Q4 | $1.13M | Buy |
25,264
+19,747
| +358% | +$829K | 0.01% | 794 |
|
|
2014
Q3 | $215K | Sell |
5,517
-1,244
| -18% | -$48.8K | ﹤0.01% | 1939 |
|
|
2014
Q2 | $286K | Sell |
6,761
-2,753
| -29% | -$101K | ﹤0.01% | 1942 |
|
|
2014
Q1 | $340K | Buy |
+9,514
| New | +$321K | ﹤0.01% | 2163 |
|
ProShare Advisors's ISEE Position: Q3 2023 in Review
ProShare Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 35,988 shares — an estimated $1.42M sold.
ProShare Advisors first reported a position in ISEE in Q1 2014 and held it in 26 quarters. The position peaked at $2.48M in Q4 2015. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- ProShare Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- ProShare Advisors sold 35,988 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $1.42M.
- ProShare Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q1 2014 and held it in 26 quarters.
- ProShare Advisors's IVERIC bio, Inc. Common Stock position peaked at $2.48M in Q4 2015.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on ProShare Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.